The present invention relates to an organic/heterometallic hybrid polymer including a plurality of organometal complexes and a plurality of transition metals, the organic/heterometallic hybrid polymer, wherein the plurality of organometal complexes are linked in a linear manner by sandwiching each of the plurality of transition metals therebetween, the organometal complexes include two ligands each having a terpyridyl group and one connector having Ru(dppe).sub.2 and two ethynylene groups, and the two ligands are linked by the connector, so that a nitrogen atom at position 1 of the terpyridyl group is directed toward the terminal side of the molecule of the organometal complex, and the terpyridyl groups of at least two different organometal complexes of the plurality of organometal complexes are bound to one of the transition metals through a coordinate bond, thereby linking the plurality of organometal complexes while sandwiching the plurality of transition metals alternately therebetween.

Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamte ligands are connected by Au(I)-Au(l) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.

Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamte ligands are connected by Au(I)-Au(l) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.

A synthesis method of benzotrichalcogenophene (BTC) includes using a tetrakis(triphenylphosphine)palladium (Pd(PPh.sub.3).sub.4) catalyst and a [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloro[3-phenylallyl]palladium(II) (Pd-IPr) catalyst. The asymmetric benzotrichalcogenophene compound is a heterocyclic compound having furan, thiophene, selenophene and/or tellurophene subunits.

A synthesis method of benzotrichalcogenophene (BTC) includes using a tetrakis(triphenylphosphine)palladium (Pd(PPh.sub.3).sub.4) catalyst and a [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloro[3-phenylallyl]palladium(II) (Pd-IPr) catalyst. The asymmetric benzotrichalcogenophene compound is a heterocyclic compound having furan, thiophene, selenophene and/or tellurophene subunits.

Implementations and techniques for preparing and using monomers, oligomeric complexes, and coordination polymers are generally disclosed.

Implementations and techniques for preparing and using monomers, oligomeric complexes, and coordination polymers are generally disclosed.

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): ##STR00001##
or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, L.sup.1, L.sup.2, L.sup.3, M and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.

A synthesis method of benzotrichalcogenophene (BTC) includes using a tetrakis(triphenylphosphine)palladium (Pd(PPh.sub.3).sub.4) catalyst and a [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloro[3-phenylallyl]palladium(II) (PdIPr) catalyst. The asymmetric benzotrichalcogenophene compound is a heterocyclic compound having furan, thiophene, selenophene and/or tellurophene subunits.

A synthesis method of benzotrichalcogenophene (BTC) includes using a tetrakis(triphenylphosphine)palladium (Pd(PPh.sub.3).sub.4) catalyst and a [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]chloro[3-phenylallyl]palladium(II) (PdIPr) catalyst. The asymmetric benzotrichalcogenophene compound is a heterocyclic compound having furan, thiophene, selenophene and/or tellurophene subunits.